SCHEMBL6441899

SCHEMBL6441899

C[S+]([O-])c1nc(N)c(C#N)c(-c2ccco2)c1C#N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.58
KDM4E B2RXH2 7/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
LMNA P02545 1/20 0.58
HSD17B10 Q99714 6/20 0.56
POLB P06746 1/20 0.56
HPGD P15428 6/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
TSHR P16473 1/20 0.56
ADORA1 P30542 10/20 0.55
ADORA3 P0DMS8 6/20 0.55
ADORA2A P29274 6/20 0.55
CASP1 P29466 1/20 0.55
BLM P54132 1/20 0.55
NPSR1 Q6W5P4 3/20 0.53
MAPT P10636 4/20 0.52
USP2 O75604 1/20 0.52
ALOX15 P16050 1/20 0.52
HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6444885 0.80 ADORA2A (0.61) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6441969 0.79 ADORA2A (0.55) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL6258393 0.77 ADORA1 (0.61) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6441030 0.76 KDM4E (0.75) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL7020734 0.74 ALDH1A1 (0.59) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL6442269 0.73 ADORA1 (0.74) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6256113 0.72 HSD17B10 (0.72) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL19716807 0.71 ADORA1 (0.53) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6255086 0.71 ALDH1A1 (1.00) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6254535 0.70 HSD17B10 (0.77) ALDH1A1KDM4EMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885KDM4E 3250/4885MEN1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.